Delphia Therapeutics raised $67M in a Series A financing led by GV, Nextech Invest, Polaris Innovation Fund, and Alexandria Venture Investments to pioneer activation lethality in cancer medicines.

May 02, 2024•about 1 year ago

Amount Raised

$67 Million

Round Type

series a

CambridgeTherapeuticsBiotechnologyHealth Care

Investors

Alexandria Venture InvestmentsPolaris Innovation FundNextech InvestGv (Google Ventures)

Description

Delphia Therapeutics launched to pioneer a new area of cancer biology called activation lethality, to develop first-in-class targeted cancer medicines with significant anti-tumor activity and more durable patient benefit.

Company Information

Company

Delphia Therapeutics

Location

Cambridge, Massachusetts, United States

About

Delphia Therapeutics is a biopharmaceutical company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class, targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Delphia Therapeutics raised $67M in a Series A financing led by GV, Nextech Invest, Polaris Innovation Fund, and Alexandria Venture Investments to pioneer activation lethality in cancer medicines.

Investors

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Related People

Company Information